NCT01160874

Brief Summary

The Attention Deficit/ Hyperactivity Disorder (ADHD) is a developmental disorder which affects 3 to 5 % of school age children. This disorder persists in the adulthood for 60 % of subjects. Children with ADHD are sleepier during the day than normal children. However, there is no information concerning the diurnal sleepiness of adults with ADHD and the impact of this sleepiness on their driving capacity. The investigators postulate that the negative impact of ADHD is due to an awakening disorder which adds to the attentional disorder. The aim of this study is to estimate both the sleepiness by a Maintenance Wakefulness Test (MWT) and the capacity to drive in adults with ADHD.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jul 2010

Typical duration for not_applicable

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2010

Completed
8 days until next milestone

First Submitted

Initial submission to the registry

July 9, 2010

Completed
3 days until next milestone

First Posted

Study publicly available on registry

July 12, 2010

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2013

Completed
Last Updated

October 25, 2013

Status Verified

October 1, 2013

Enrollment Period

3 years

First QC Date

July 9, 2010

Last Update Submit

October 24, 2013

Conditions

Keywords

Attention Deficit Disorder / Hyperactivity (ADHD)CognitionSleepinessDriving

Outcome Measures

Primary Outcomes (1)

  • Measurement of the average sleep latency during the Maintenance Wakefulness Test

    Day 7

Secondary Outcomes (4)

  • The number of line crossing on the driving simulator test

    Day 7

  • Standard deviation of the average position of the vehicle in the driving simulator test

    Day 7

  • Score on Epworth Sleepiness scale

    Day 7

  • Reaction time and the percentage of error in the cognitive tests

    Day 7

Study Arms (3)

TDA/H

EXPERIMENTAL
Other: PolysomnographyOther: Maintenance Wakefulness TestBehavioral: Neuropsychological evaluationOther: Driving test on a simulator

Sleep apnea patient

OTHER
Other: Maintenance Wakefulness TestOther: Driving test on a simulator

Healthy volunteer

OTHER
Other: PolysomnographyOther: Maintenance Wakefulness TestBehavioral: Neuropsychological evaluationOther: Driving test on a simulator

Interventions

Sleep study monitoring

Healthy volunteerTDA/H

Sleep latency testing at 10 am, 12 am, 2 pm and 4 pm.

Healthy volunteerSleep apnea patientTDA/H

Neuropsychological evaluation for cognitive functions study

Healthy volunteerTDA/H

Driving simulator test during wich a camera register different parameters as the position of the vehicle.

Healthy volunteerSleep apnea patientTDA/H

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Group for ADHD:
  • Patients, male or female, aged 18 to 60 years
  • Patients who met the criteria for current diagnosis of ADD / ADHD according to DSM IV-TR
  • Patients who met the criteria for diagnosis in childhood ADD / ADHD, as assessed by the scale "Conners'Adult ADHD Diagnostic Interview for DSM-IV" (CCACID) (Conners, 1997)
  • Patients with a total score ≥ 20 at the CAARS (hetero-questionnaire to 30 items) (Conners, 1997) with at least 6 items of inattention or hyperactivity subscale ≥ 2
  • Patients deprived from all psychostimulants for 72 hours
  • Having been schooled up to last year of middle school
  • Having regular hours of life 3 days before entering the study
  • Having a driver's license
  • Registered Social Security
  • Having given their written informed consent to participate in the study
  • Consent free, informed and written, dated and signed by the patient and the investigator before any examination required by the research.
  • For the apneic group:
  • Patients, male or female, aged 18 to 60 years
  • Patients with apnea index of apnea / hypopnea\> 10
  • +18 more criteria

You may not qualify if:

  • Posted or Night worker,
  • Any evolutionary neurological disorders (brain tumour, epilepsy, migraine, brain vascular accident, multiple sclerosis, myoclonus, chorea, neuropathy, muscular dystrophies, myotonic dystrophy),
  • Psychiatric comorbidity: current major depressive episode, current hypo obsessive or obsessive episode, schizophrenia,
  • Renal Disorders (renal insufficiency, nephrolithiases),
  • Endocrine Pathologies (dysthyroid, diabetes),
  • Drug addiction
  • Alcoholic Dependence during the last 6 months,
  • Dependence in the tetra-hydroxy-cannabinol
  • Long-term Treatment by benzodiazépines
  • Treatment by atomoxétine
  • Persons placed under protection of justice

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

CHU de Bordeaux

Bordeaux, 33076, France

Location

Hôpital Charles Perrens

Bordeaux, 33076, France

Location

Related Publications (1)

  • Bioulac S, Chaufton C, Taillard J, Claret A, Sagaspe P, Fabrigoule C, Bouvard MP, Philip P. Excessive daytime sleepiness in adult patients with ADHD as measured by the Maintenance of Wakefulness Test, an electrophysiologic measure. J Clin Psychiatry. 2015 Jul;76(7):943-8. doi: 10.4088/JCP.14m09087.

MeSH Terms

Conditions

Attention Deficit Disorder with HyperactivitySpasmSleepiness

Condition Hierarchy (Ancestors)

Attention Deficit and Disruptive Behavior DisordersNeurodevelopmental DisordersMental DisordersNeuromuscular ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Anouck AMESTOY, Dr

    University Hospital Bordeaux (France)

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 9, 2010

First Posted

July 12, 2010

Study Start

July 1, 2010

Primary Completion

July 1, 2013

Study Completion

July 1, 2013

Last Updated

October 25, 2013

Record last verified: 2013-10

Locations